Yarrow Bioscience, Inc. (YARW)
37.76
-1.49
(-3.80%)
USD |
NASDAQ |
Aug 26, 15:13
Yarrow Bioscience Gross Profit Margin (Quarterly) : 93.81% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 93.81% |
| March 31, 2026 | 93.02% |
| December 31, 2025 | 96.15% |
| September 30, 2025 | 96.45% |
| June 30, 2025 | 91.30% |
| March 31, 2025 | 97.03% |
| December 31, 2024 | 95.24% |
| September 30, 2024 | 0.00% |
| June 30, 2024 | 0.00% |
| March 31, 2024 | 0.00% |
| December 31, 2023 | 0.00% |
| September 30, 2023 | 0.00% |
| June 30, 2023 | 0.00% |
| March 31, 2023 | 0.00% |
| December 31, 2022 | 0.00% |
| September 30, 2022 | -2.40% |
| June 30, 2022 | 90.48% |
| March 31, 2022 | 0.00% |
| December 31, 2021 | |
| September 30, 2021 | 78.95% |
| Date | Value |
|---|---|
| June 30, 2021 | 90.51% |
| March 31, 2021 | |
| December 31, 2020 | 87.54% |
| September 30, 2020 | 88.65% |
| June 30, 2020 | 98.15% |
| March 31, 2020 | 84.51% |
| December 31, 2019 | 30.37% |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | 75.32% |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Oramed Pharmaceuticals, Inc. | -- |
| NRX Pharmaceuticals, Inc. | 23.43% |
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -64.87% |
| Return on Assets | -58.79% |
| Return on Invested Capital | -64.86% |
| Profit Margin (Quarterly) | -2.99K% |
| Operating Margin (Quarterly) | -3.20K% |
| Return on Net Operating Assets | -19.57K% |